Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: Current State of Development

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 2007 May 17

PMID 17503894

Citations 31

Authors

Luigi Gennari

Daniela Merlotti

Fabrizio Valleggi

Giuseppe Martini

Ranuccio Nuti

Affiliations

Soon will be listed here.

Abstract

Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as estrogen receptor agonists and antagonists. These drugs have been intensively studied over the past decade and have proven to be a highly versatile group for the treatment of different conditions associated with aging, including hormone-responsive cancer and osteoporosis. Tamoxifen and toremifene are currently used to treat advanced breast cancer and also have beneficial effects on bone mineral density and serum lipids in postmenopausal women. Raloxifene is the only SERM approved worldwide for the prevention and treatment of postmenopausal osteoporosis and vertebral fractures. However, although these SERMs have many benefits, they may also be responsible for some potentially very serious adverse effects, such as thromboembolic disorders and, in the case of tamoxifen, uterine cancer. These adverse effects represent a major concern given that long-term therapy is required to prevent osteoporosis. Moreover, both preclinical and clinical reports suggest that tamoxifen, toremifene and raloxifene are considerably less potent than estrogen. The search for the 'ideal' SERM, which would have estrogenic effects on bone and serum lipids, neutral effects on the uterus, and antiestrogenic effects on breast tissue, but none of the adverse effects associated with current therapies, is currently under way. Ospemifene, lasofoxifene, bazedoxifene and arzoxifene, which are new SERM molecules with potential greater efficacy and potency than previous SERMs, are currently under investigation for use in the treatment and prevention of osteoporosis. These drugs have been shown to be comparably effective to conventional hormone replacement therapy in animal models of osteoporosis, with potential indications for an improved safety profile. Clinical efficacy data from ongoing phase III trials are awaited so that a true understanding of the therapeutic potential of these compounds can be obtained.

Citing Articles

Surgical Management of Adult Spinal Deformity Patients with Osteoporosis.

Baroudi M, Daher M, Maheshwari K, Singh M, Nassar J, McDonald C J Clin Med. 2024; 13(23).

PMID: 39685632 PMC: 11641945. DOI: 10.3390/jcm13237173.

In Silico Clinical Trial for Osteoporosis Treatments to Prevent Hip Fractures: Simulation of the Placebo Arm.

Savelli G, Oliviero S, La Mattina A, Viceconti M Ann Biomed Eng. 2024; 53(3):578-587.

PMID: 39576502 PMC: 11836154. DOI: 10.1007/s10439-024-03636-4.

Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations.

Holubeck P, Eksi A, Gillett K, OHara J, McGoldrick D, Brown D Cureus. 2024; 16(1):e52011.

PMID: 38344525 PMC: 10854362. DOI: 10.7759/cureus.52011.

Novel Advances in the Role of Selective Estrogen Receptor Modulators in Hormonal Replacement Therapy: A Paradigm Shift.

Motlani G, Motlani V, Acharya N, Dave A, Pamnani S, Somyani D Cureus. 2023; 15(11):e49079.

PMID: 38125238 PMC: 10730982. DOI: 10.7759/cureus.49079.

Repurpose dasatinib and quercetin: Targeting senescent cells ameliorates postmenopausal osteoporosis and rejuvenates bone regeneration.

Wang Y, Che L, Chen X, He Z, Song D, Yuan Y Bioact Mater. 2023; 25:13-28.

PMID: 37056256 PMC: 10088057. DOI: 10.1016/j.bioactmat.2023.01.009.

References

Qu Q, Harkonen P, Vaananen H . Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem. 2000; 73(4):500-7. View

Grese T, Pennington L, Sluka J, Adrian M, Cole H, Fuson T . Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J Med Chem. 1998; 41(8):1272-83. DOI: 10.1021/jm970688z. View

Ravn P, Nielsen T, Christiansen C . What can be learned from the levormeloxifene experience?. Acta Obstet Gynecol Scand. 2006; 85(2):135-42. DOI: 10.1080/00016340500345691. View

Cummings S, Black D, Nevitt M, Browner W, Cauley J, Ensrud K . Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993; 341(8837):72-5. DOI: 10.1016/0140-6736(93)92555-8. View

Jordan V, Phelps E, Lindgren J . Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat. 1987; 10(1):31-5. DOI: 10.1007/BF01806132. View

Gustafsson J . Estrogen receptor beta--a new dimension in estrogen mechanism of action. J Endocrinol. 1999; 163(3):379-83. DOI: 10.1677/joe.0.1630379. View

Palkowitz A, Glasebrook A, Thrasher K, Hauser K, Short L, Phillips D . Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem. 1997; 40(10):1407-16. DOI: 10.1021/jm970167b. View

Mosselman S, Polman J, Dijkema R . ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996; 392(1):49-53. DOI: 10.1016/0014-5793(96)00782-x. View

Bryant H, Glasebrook A, Yang N, Sato M . An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol. 1999; 69(1-6):37-44. DOI: 10.1016/s0960-0760(98)00147-2. View

10.

Dodge J, Lugar C, Cho S, Short L, Sato M, Yang N . Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol. 1997; 61(1-2):97-106. DOI: 10.1016/s0960-0760(97)00008-3. View

11.

Munster P . Arzoxifene: the development and clinical outcome of an ideal SERM. Expert Opin Investig Drugs. 2006; 15(3):317-26. DOI: 10.1517/13543784.15.3.317. View

12.

Gennari L, Nuti R, Bilezikian J . Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab. 2004; 89(12):5898-907. DOI: 10.1210/jc.2004-1717. View

13.

COHEN L, Pittman B, Wang C, Aliaga C, Yu L, Moyer J . LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res. 2001; 61(24):8683-8. View

14.

Khosla S, Melton 3rd L, Riggs B . Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab. 2002; 87(4):1443-50. DOI: 10.1210/jcem.87.4.8417. View

15.

Fisher B, Costantino J, Wickerham D, Cecchini R, Cronin W, Robidoux A . Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005; 97(22):1652-62. DOI: 10.1093/jnci/dji372. View

16.

Gennari L . Lasofoxifene (Pfizer). Curr Opin Investig Drugs. 2005; 6(10):1067-78. View

17.

Sato M, Turner C, Wang T, Adrian M, Rowley E, Bryant H . LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther. 1998; 287(1):1-7. View

18.

Qu Q, Zheng H, Dahllund J, Laine A, Cockcroft N, Peng Z . Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology. 2000; 141(2):809-20. DOI: 10.1210/endo.141.2.7342. View

19.

Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295(23):2727-41. DOI: 10.1001/jama.295.23.joc60074. View

20.

Voipio S, Komi J, Kangas L, Halonen K, DeGregorio M, Erkkola R . Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas. 2002; 43(3):207-14. DOI: 10.1016/s0378-5122(02)00206-2. View